ProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Rating of “Buy” from Brokerages

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been assigned an average recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $7.60.

PRQR has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $6.00 to $14.00 in a research report on Tuesday, October 29th. Finally, Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th.

ProQR Therapeutics Price Performance

Shares of NASDAQ:PRQR opened at $2.76 on Monday. The stock’s 50-day moving average is $3.32 and its 200 day moving average is $2.48. The company has a market cap of $225.44 million, a PE ratio of -8.63 and a beta of 0.30. ProQR Therapeutics has a 1 year low of $1.61 and a 1 year high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds have recently bought and sold shares of PRQR. Privium Fund Management B.V. increased its stake in shares of ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after purchasing an additional 51,663 shares in the last quarter. OneDigital Investment Advisors LLC increased its position in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).